Jefferies Group set a GBX 5,650 ($80.90) target price on AstraZeneca (LON:AZN) in a research report sent to investors on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other research analysts have also recently commented on the company. JPMorgan Chase set a GBX 5,500 ($78.75) target price on AstraZeneca and gave the stock a buy rating in a research report on Friday. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a research report on Wednesday, April 11th. Deutsche Bank reaffirmed a buy rating on shares of AstraZeneca in a research report on Monday, April 9th. Morgan Stanley reissued an equal weight rating and set a GBX 5,250 ($75.17) price objective on shares of AstraZeneca in a report on Tuesday, March 27th. Finally, BNP Paribas reissued an outperform rating and set a GBX 5,600 ($80.18) price objective on shares of AstraZeneca in a report on Thursday, March 22nd. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Hold and an average target price of GBX 5,226.87 ($74.84).
Shares of AZN stock opened at GBX 4,915.50 ($70.38) on Friday. AstraZeneca has a one year low of GBX 4,260 ($61.00) and a one year high of GBX 5,520 ($79.04).
The firm also recently declared a dividend, which was paid on Monday, March 19th. Investors of record on Thursday, February 15th were issued a GBX 133.60 ($1.91) dividend. This represents a dividend yield of 2.8%. This is a boost from AstraZeneca’s previous dividend of $68.90. The ex-dividend date was Thursday, February 15th.
In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was acquired at an average cost of GBX 4,846 ($69.39) per share, with a total value of £20,110.90 ($28,795.68).
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/17/astrazeneca-azn-given-a-gbx-5650-price-target-by-jefferies-group-analysts.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.